Vaxcyte (PCVX)
(Delayed Data from NSDQ)
$33.02 USD
-0.93 (-2.74%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $33.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PCVX 33.02 -0.93(-2.74%)
Will PCVX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PCVX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCVX
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
PCVX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Other News for PCVX
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
TimesSquare U.S. Small Cap Growth Strategy Q2 2025 Commentary
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc.
Vaxcyte (PCVX) Maintains Strength Amid Potential Vaccine Review | PCVX Stock News
Vaxcyte vaccine candidates contain aluminum, says Mizuho